Kelly Dudley, NP
Primary Care · Augusta, MENPI 1053781492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Grifols USA, LLC at 41.5% of the total. Among primary care clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$624
- AstraZeneca$314
- Sanofi$253
- GSK$113
- Regeneron Healthcare Solutions, Inc.$32
- Verona Pharma, Inc.$32
- plus $133 from 5 others
What the payments were for
- Food & beverage$1,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 24 | $624 |
| AstraZeneca | 14 | $314 |
| Sanofi | 9 | $253 |
| GSK | 6 | $113 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Verona Pharma, Inc. | 1 | $32 |
| Amgen | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Philips North America LLC | 1 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,501 in reported general payments places this provider in the 90th percentile of 29 primary care providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 366 | $458,768 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 295 | $364,960 |
| Advair HfaFluticasone Propion/Salmeterol | 404 | $269,852 |
| Spiriva RespimatTiotropium Bromide | 237 | $233,962 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 70 | $60,945 |
| Spiriva HandihalerTiotropium Bromide | 57 | $56,179 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $55,191 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $53,850 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $53,070 |
| Incruse ElliptaUmeclidinium Bromide | 69 | $52,929 |
| DuleraMometasone/Formoterol | 72 | $46,499 |
| SymbicortBudesonide/Formoterol Fumarate | 104 | $43,404 |
| Fluticasone Propionate HfaFluticasone Propionate | 48 | $17,569 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 19 | $13,750 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 406 | $12,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $113 | $627,566590 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $314 | $469,310469 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $27 | $287,812305 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 29 primary care providers in Maine.
Other primary care in Augusta
- Deanna FelveyAugusta$773
- Rebecca HoldsworthWells$5K
- Renee CourtemancheLewiston$3K
- Caroline WilmotPortland$909
- Shelby StilesMars Hill$558
- Kelsie MilledgeAuburn$517
- Michelle BreenAlbion$473
- Melissa LowerSouthwest Harbor$455
- Regina BlauveltBangor$363
- Molly LobelSpringvale$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.